Retatrutide and Blood Pressure: Effects on Hypertension

Weight Loss Lowers Blood Pressure

The most significant effect of retatrutide on blood pressure is mediated through weight loss. Each kilogram of weight lost is associated with an approximately 1 mmHg reduction in systolic blood pressure. Given that retatrutide produces an average of 28.3% weight loss in the TRIUMPH-1 trial, the expected blood pressure reduction from weight loss alone is substantial. The TRIUMPH-4 trial announced in December 2025 showed significant improvements in systolic blood pressure and other cardiovascular risk markers in the retatrutide group.

Direct Cardiovascular Effects

GLP-1 receptor activation has direct effects on the cardiovascular system that are independent of weight loss. Semaglutide’s SELECT trial demonstrated that the drug reduces major adverse cardiovascular events even in patients who do not lose significant weight. Retatrutide activates the same GLP-1 receptor plus the GIP receptor, which may have additional cardiovascular benefits. The glucagon receptor component, however, introduces a countervailing effect: the heart rate increase of 2-5 bpm could theoretically offset some of the cardiovascular benefits, though the net effect in the trials so far has been favorable.